C D KING - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

C D KING

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Clinical Pharmacology and Therapeutics|February 26, 2010

Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.

The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010

Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.

Biorxiv : the Preprint Server for Biology|July 18, 2023

β-hydroxybutyrate is a metabolic regulator of proteostasis in the aged and Alzheimer disease brainS S Madhavan, S Roa Diaz, S Peralta, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Clinical Pharmacology and Therapeutics|February 26, 2010

Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.

The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010

Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.

Biorxiv : the Preprint Server for Biology|July 18, 2023

β-hydroxybutyrate is a metabolic regulator of proteostasis in the aged and Alzheimer disease brainS S Madhavan, S Roa Diaz, S Peralta, et al.

Pageof 4